OBJECTIVE: This study examines antibiotic resistance in Pseudomonas aeruginosa in hospitalized patients in relation to prior empirical antibiotic therapy. DESIGN: Two retrospective case analyses comparing patients who manifested P aeruginosa with differing patterns of antibiotic resistance. SETTING AND PARTICIPANTS: Patients acquiring P aeruginosa in a community hospital. MEASURES: Patients were compared on duration of hospitalization and days and doses of antibiotics prior to recovery of P aeruginosa. Patients were grouped, based on susceptibility patterns of their P aeruginosa isolates classified as follows: (1) fully susceptible (susceptible to all classes of antipseudomonal antibiotics [SPA]), (2) multidrug-resistant (resistant to two classes of antipseudomonal antibiotics [MDRPA]), or (3) highly drug-resistant (resistant to > or = 6 classes of antipseudomonal antibiotics [HRPA]). To control for duration of hospitalization, antibiotic treatments of HRPA and SPA patients were compared during the first 21 days of care. RESULTS: Prior to recovery of HRPA, six HRPA patients received greater amounts of antibiotics, both antipseudomonal and non-antipseudomonal, than did six SPA patients prior to recovery of SPA. For 14 patients with hospital-acquired SPA who later manifested MDRPA, duration and dosage of antipseudomonal antibiotics, but not all antibiotics, were significantly higher for the SPA-to-MDRPA interval than for the preceding admission-to-SPA interval. The median duration of antipseudomonal antibiotic treatment prior to the recovery of P aeruginosa was 0 days for SPA, 11 days for MDRPA, and 24 days for HRPA. CONCLUSION: Duration of empirical antipseudomonal antibiotic treatment influences selection of resistant strains of P aeruginosa; the longer the duration, the broader the pattern of resistance.
OBJECTIVE: This study examines antibiotic resistance in Pseudomonas aeruginosa in hospitalized patients in relation to prior empirical antibiotic therapy. DESIGN: Two retrospective case analyses comparing patients who manifested P aeruginosa with differing patterns of antibiotic resistance. SETTING AND PARTICIPANTS: Patients acquiring P aeruginosa in a community hospital. MEASURES: Patients were compared on duration of hospitalization and days and doses of antibiotics prior to recovery of P aeruginosa. Patients were grouped, based on susceptibility patterns of their P aeruginosa isolates classified as follows: (1) fully susceptible (susceptible to all classes of antipseudomonal antibiotics [SPA]), (2) multidrug-resistant (resistant to two classes of antipseudomonal antibiotics [MDRPA]), or (3) highly drug-resistant (resistant to > or = 6 classes of antipseudomonal antibiotics [HRPA]). To control for duration of hospitalization, antibiotic treatments of HRPA and SPApatients were compared during the first 21 days of care. RESULTS: Prior to recovery of HRPA, six HRPA patients received greater amounts of antibiotics, both antipseudomonal and non-antipseudomonal, than did six SPApatients prior to recovery of SPA. For 14 patients with hospital-acquired SPA who later manifested MDRPA, duration and dosage of antipseudomonal antibiotics, but not all antibiotics, were significantly higher for the SPA-to-MDRPA interval than for the preceding admission-to-SPA interval. The median duration of antipseudomonal antibiotic treatment prior to the recovery of P aeruginosa was 0 days for SPA, 11 days for MDRPA, and 24 days for HRPA. CONCLUSION: Duration of empirical antipseudomonal antibiotic treatment influences selection of resistant strains of P aeruginosa; the longer the duration, the broader the pattern of resistance.
Authors: Silvia Gómez-Zorrilla; Mariana Camoez; Fe Tubau; Elisabet Periche; Rosario Cañizares; M Angeles Dominguez; Javier Ariza; Carmen Peña Journal: Antimicrob Agents Chemother Date: 2014-07-21 Impact factor: 5.191
Authors: C Peña; S Gómez-Zorrilla; C Suarez; M A Dominguez; F Tubau; O Arch; A Oliver; M Pujol; J Ariza Journal: Eur J Clin Microbiol Infect Dis Date: 2012-05-04 Impact factor: 3.267
Authors: Thomas P Lodise; Christopher D Miller; Jeffrey Graves; Jon P Furuno; Jessina C McGregor; Ben Lomaestro; Eileen Graffunder; Louise-Anne McNutt Journal: Antimicrob Agents Chemother Date: 2006-12-11 Impact factor: 5.191
Authors: José A Martínez; Esther Delgado; Sara Martí; Francesc Marco; Jordi Vila; Josep Mensa; Antoni Torres; Carles Codina; Antoni Trilla; Alex Soriano; Aitor Alquezar; Pedro Castro; José M Nicolás Journal: Intensive Care Med Date: 2008-10-21 Impact factor: 17.440